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Carbon nanotubes have a huge biotechnological interest because they can penetrate most biological barriers and, inside 
cells, can biomimetically interact with the cytoskeletal filaments, triggering anti-proliferative and cytotoxic effects in highly 
dividing cells. Unfortunately, their intrinsic properties and bio-persistence represent a putative hazard that relapses their 
application as therapies against cancer. Here we investigate mild oxidation treatments to improve MWCNTs intracellular 
enzymatic digestion, but preserving their morphology, responsible for their intrinsic anti-cancer properties. Cell imaging 
techniques and confocal Raman spectroscopic signature analysis revealed that cultured macrophages can degrade bundles 
of oxidized MWCNTs (o-MWCNTs) in a few days. Isolation of nanotubes from these phagocytes 96 hours after exposure 
confirmed a significant reduction of approximately 30% in the total length of these filaments compared to control o-
MWCNTs extracted from the cell culture medium, or the intracellular pristine MWCNTs. More interestingly, in vivo single 
intratumoral injections of o-MWCNTs triggered ca. 30% solid melanoma tumour growth-inhibitory effects while displaying 
significant signs of biodegradation at the tumoral/peri-tumoral tissues a week after the therapy has had the effect. These 
results support the potential use of o-MWCNTs as antitumoral agents and reveal interesting clues of how to enhance in vivo 




Carbon nanotubes (CNTs) are likely to participate in many new 
ground-breaking advances in nanomedicine including 
drug/gene delivery, tissue regeneration, bio-sensing, probes for 
diagnostics or monitoring, among many others.1 CNTs are also 
interesting tools for therapeutic delivery since they can move 
across most cellular barriers, interact with tissues in living 
organisms, finally translocating inside the cells, where they 
interact with different organelles and proteins.2–4 These 
intrinsic properties of CNTs have a great potential if they are 
exploited in biotechnology.5–9 
Among CNTs, multiwalled carbon nanotubes (MWCNTs) display 
unique biomimetic properties with microtubules10,11 that are 
well-established targets for many anticancer drugs such as 
taxol®.12 Microtubules are highly dynamic intracellular tubulin 
protein nanotubes that play a central role in cell division and 
migration. These protein filaments and MWCNTs (i) self-
assemble, (ii) have analogous dimensions, (iii) are exceptionally 
resilient and finally, (iv) show comparable extraordinary 
structural and surface properties (i.e. shear stress, bending 
stiffness, Young´s modulus).10,13,14 
Similarities between MWCNTs and microtubules prompt their 
interaction in vitro15 and in vivo11,16 and the assembly of mixed 
bio-synthetic intracellular polymers that display an enhanced 
stability compared to conventional tubulin polymers.11 This 
interaction triggers critical changes in the cellular biomechanics 
resulting in anti-proliferative,11 anti-migratory17,18 and 
cytotoxic19 effects in cancer cells in vitro, as well as significant 
anti-tumoral effects in vivo.20 These results suggest CNTs could 
have a potential application as adjuvant or neoadjuvant 
therapies in the development of future anti-cancer agents.21  
Unfortunately, despite these interesting results, there is a long 
way before MWCNTs can be applied to humans. Their potential 
long-term effects due to tissue damage and accumulation are 
key issues to control and improve. Among the unwanted side 
effects in healthy cells and tissues, MWCNTs trigger: 
inflammatory reactions, cytotoxicity, DNA breakage, 
chromosomal mal-segregation, etc.22–26 Thus, the “Achilles 
heels” for the potential applications of MWCNTs as 
nanomedicines is the complete inactivation and/or clearance of 
these nanomaterials after therapy.  
The discovery of CNT bio-degradation in vitro by phagocytic cells 
has opened new opportunities. These cells have an 
extraordinary degradative potential, and can break down 
virtually all kinds of biomolecules captured by the endocytic or  
phagocytic entry routes. Their lysosomes, apart from displaying 
a pH of 4.5, contain a large variety of enzymes (acid-hydrolases 
and peroxidases) that are able to gradually digest CNTs.27–33 
Macrophages,32 microglia,33–36 neutrophils37,38 and 
eosinophils31 have all been confirmed to degrade CNTs in 
culture after different previous surface treatments. 
Paradoxically, phagocytes are more susceptible than other cells 
to CNT-toxicity, at least in vitro.19,39 Their avidity to capture 
these foreign materials often results in the production of 
intolerable levels of superoxides and hydroxyl radicals involved 
in the oxidative stress reaction triggered during CNT 
degradation.25,32,35,40–42  
Some studies support the idea that reaching an equilibrium 
between phagocyte nanotube intake and clearance is critical to 
prevent tissue bioaccumulation and damage. But improving 
MWCNT biodegradation is not a trivial task. These fibres are 
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some of the strongest and stiffest materials and thus, they are 
highly stable under standard in vivo physiological conditions. 
Their bio-persistence depends on (i) the number of walls of the 
nanotube, (ii) the surface and diameter of the tubes, (iii) the 
dose, (iv) route of administration and finally, (v) their surface 
functionalisation.24,26,43–46 Interestingly, several studies show 
how CNT degradation by biological enzymes is significantly 
enhanced when the nanotube surface is chemically modified by 
oxidation.34,35,45,47–51 This treatment results in the formation of 
different functional groups on the CNT surface, and structural 
defects in the nanotube walls that serve as macrophage 
enzymatic “attack” sites for wall degradation.  
Based on these findings, we have explored various surface 
oxidation pre-treatments to enhance MWCNT clearance by 
macrophages preserving their biomimetic properties with 
microtubules, in ultimate term responsible for their anti-
proliferative, anti-migratory and cytotoxic effects in cancer 
cells.   
 
 
Results and discussion 
 
MWCNT oxidation pre-treatment. 
To improve intracellular CNT degradation, pristine MWCNTs (p-
MWCNTs) were oxidized in a v/v = 3/1 mixture of H2SO4/HNO3 
at 37º C for two different periods of time (2 and 9 h, as 
indicated). As described elsewhere,52 this treatment generates 
the formation of functional groups such as –C–OH groups that 
can be transformed into –C=O groups on the outer surface of 
the oxidized MWCNTs (o-MWCNTs). To characterize this 
process and to obtain valuable information about the structure, 
composition and surface adsorbed molecules and defects on o-
MWCNTs we employed transmission electron microscopy 
(TEM) and Raman spectroscopy to characterize the degree of 
structural defects/changes and to monitor the different 
vibrational active modes produced by the oxidation processes 
(see also Fig. S1).53,54   
TEM imaging of the p-MWCNTs and the 9h o-MWCNTs (Fig. 1a) 
revealed defects including: (i) a reduction of the number of 
walls, from 12-16 walls in pristine sample to 8-10 average 
carbon layers in o-MWCNTs, (ii) changes in the outer and inner 
walls, (iii) layer exfoliation, (iv) small surface imperfections and 
finally, (v) wall bending or breaks. This technique also served to 
demonstrate a general good preservation of the o-MWCNTs 
(i.e. diameter and length, see below). 
Raman spectroscopy, yields key information of the purity and 
defects of the MWCNTs, allowing the identification of this type 
of nanotubes among other carbon compounds. In particular, 
the measurement of the integrated intensity ratio between the 
D and G bands (AD/AG) is a way to semi-quantify the degree of 
structural defects in the nanotube sample (Table 1).33,34,36,45,55,56  
Fig.  1b displays representative Raman spectra of p-MWCNT, 2 
and 9 h pre-oxidized MWCNT samples showing the 
characteristic D and G bands at ca. 1350 cm-1 and 1590 cm-1, 
respectively. These bands represent a good fingerprint of the 
graphitization of the sample, where the D band is assigned to 
the presence of disorder, and the G band corresponds to the 
tangential vibrations of carbon atoms along the layer. The D´ 
band, at ca. 1615 cm–1 can also be observed as a shoulder 
attached to the G band. Interestingly, the G band shifts towards 
lower wavenumbers with longer oxidation treatments 
indicating the charge transfer produced by the processes of 
oxidation and degradation modifying the charge at the MWCNT 
surface.57,58 Based on these studies, we compared the AD/AG 
integrated intensity ratios of p-MWCNTs, 2 h and 9 h o-
MWCNTs to estimate the degree of surface defects triggered by 
the oxidation pre-treatment on the surface of the nanotubes 
samples. Results summarized in Table 1 confirmed a 
relationship between the oxidation time and the structural 
defects on the surface of the nanotubes, validating the 
effectiveness of the applied treatment.  
 





2 h 9 h 
2.32 2.79 
 
Table 1. Analysis of the AD/AG ratios for pristine (p-MWCNTs), 2 h and 9 h 
oxidized (o-MWCNTs) nanotubes 
 
 
Shift Raman (cm-1) 
p-MWCNTs o-MWCNTs 
Fig. 1. Characterization of the o-MWCNTs. (a) Low and high-resolution transmission electron microscopy (TEM) pictures of p-MWCNTs and 9 h o-MWCNTs 
demonstrating a general preservation of the morphology but small defects on the outer o-MWCNT walls (arrows). (b) Raman spectra of p-MWCNTs and 
















































































Improved o-MWCNTs degradation by cultured macrophages.  
MWCNTs used as anti-tumoral agents should normally be 
degraded at the tumour site by the tumour-associated-
macrophages and/or local stromal cells. Thus, to evaluate the 
improved biodegradation of MWCNTs bundles inside these 
cells, we used phase contrast microscopy on immortalized 
macrophages exposed to 5 µg/mL of 2 h and 9 h o-MWCNTs in 
the culture medium. As Fig. S2 shows, macrophages exposed 
during 72 h to 9 h o-MWCNTs displayed a significant reduction 
of the intracellular black-carbon masses compared to identical 
cells exposed to 2 h o-MWCNTs. As observed by other authors,59 
MWCNT oxidation was also accompanied by an improved 
phagocyte survival rate (Fig. S2c).  
The intracellular degradation process was verified using other 
techniques. To further confirm intracellular o-MWCNT 
degradation, we extracted nanotubes from the cells exposed to 
9 h o-MWCNTs or p-MWCNTs during 96 h (see the Experimental 
section). Extracted nanotubes were compared to the as 
prepared original nanotubes characterised in Fig. 1, and the 
nanotubes present in the culture medium where macrophages 
were growing (see the experimental diagram in Fig. S3). 
Nanotubes extracted from cells, the culture media and the as 
prepared material were photographed using TEM (Fig. 2) and 
were measured to evaluate degradation. Quantitative and 
qualitative analysis of these nanotube samples demonstrated a 
significant reduction in the total lengths of the intracellular o-
MWCNTs indicative of intracellular degradation. 
As an additional technique, we use confocal Raman 
spectroscopy, focusing the laser beam spot within the carbon-
containing phagosomes in the cytoplasm of macrophages 
(white cross in Fig. S2) to investigate degradation. As in the 
previous study, we semi-quantified degradation calculating the 
AD/AG ratios at different times (12, 24, 48, 72 and 96 h) 
recording the signatures of the D and G bands in the wavelength 
range 1200-1800 cm-1 (Figs. 2, S4) in a total of 10-20 randomly 
taken intracellular spots of 1 µm2 area. Results shown in Fig. 2b 
suggest that 9h o-MWCNTs begin biodegradation in 
macrophages soon after phagocytosis. 
 
o-MWCNT display biomimetic anticancer cytotoxic effects in vitro.  
We now tested the anti-cancer cytotoxic effects of o-MWCNTs 
on HeLa cells following previously published protocols.11 
Confocal microscopy examination of 50 µg/mL o-MWCNT 
treated cell cultures served to confirm sings indicative of the 
biomechanical disruptive effect of these nanotubes on HeLa, 
including: (i) cell retraction, (ii) membrane blebbing, (iii) nuclear 
DNA compaction, (iv) presence of micronuclei (Figs.  3a -white 
asterisks, S5), as well as other previously described cytoskeletal  
changes including a disorganized microtubular patterns or a 
reactive cortical actin.18 Interestingly, many cells presented long 
extra-cellular actin/tubulin-coated extensions, measuring 10-15 
µm, similar to those shown to contain MWCNTs in previous 
studies (red-green arrows).11 Similar experiments were also 
performed in parallel on malignant cancer cells. For this 
purpose we selected the B16-F10 murine cell line, a multi-
resistant malignant melanoma that displays an aggressive 
nature, is genetically heterogeneous and is highly metastatic 
(Fig S6).60  
 
o-MWCNTs inhibit tumour progression in vivo in a mouse model 
and degrade in the tumoral tissues. 
The anti-tumoral effects of o-MWCNTs were tested on solid 
melanoma tumours produced by transplantation of B16-F10 
cells. This system model is highly representative of most 
malignant tumours, being characterized by local acidosis, 
oedema and abundant tumour-associated supporting stromal 
cells that include macrophages.60,61 To improve reproducibility, 
solid pigmented melanoma tumours were injected only once 
with 2 µg of serum-functionalised nanotubes resuspended in a 
saline solution containing antibiotics (see the Experimental 
section). Intra-tumoral injection experiments were performed 
systematically in total population of more than 150 
transplanted mice (see below) that were sacrificed 4 days post-
injection. As a control, we injected the resuspension medium in 
sibling mice obtained from the same litter. Results shown in Fig. 
3b-c demonstrate a patent tumoral size reduction in o-MWCNT 
treated animals compared to controls. Melanoma mass 
quantification revealed a ca. 30 % weight reduction in o-
Fig. 2. o-MWCNTs are processed inside macrophages. (a) TEM images of the 
as prepared o-MWCNTs or p-MWCNTs, and identical nanotubes extracted 
from the culture medium or from macrophages 96 h after incubation (see Fig. 
S3). All images display identical magnification. (b) Semi-quantification of the 
structural defects on intracellular nanotubes using Raman spectroscopy 
(results from spectrograms in Fig. S4) (oMWCNTs t= 1.86; n= 28; pMWCNTs t= 
1.84; n= 22; *= t.95). (c) Quantification of the average lengths of the different  
nanotube samples. o-MWCNTs isolated from inside macrophages displayed 
significantly smaller sizes (t= 2.98 n = 59; **= t.995) that those obtained from 
the culture medium of the phagocytes. On the contrary, p-MWCNTs did not 
shortened inside macrophages after 96 h (t= 0.26 n = 58).  
 































































MWCNT-treated tumours significant (t= 1.5; n= 146, Fig.  3d). 
This anti-tumoral effect was undistinguishable to that observed 
in mice injected with p-MWCNTs (t= 0.2; n= 161). Finally, the 
biodegradability of the injected nanotubes at the tumoral organ 
was evaluated using Raman spectroscopy. Semi-quantification 
of the AD/AG bands in peritumoral and intratumoral tissue 
sections revealed a significant degradation of the injected o-
MWCNTs in situ, 18 and 15 days after injection respectively, 
while no significant changes were observed for p-MWCNTs as 
these time points (Fig.  4).  
Summarizing, here we present a bio-compatibilization method 
that can be used to improve the risk-to-benefit ratio of 
MWCNTs for their potential used as nanomedicines against 
cancer, either as adjuvant or as neoadjuvant therapies. 
Moreover, identical pre-treatments can be used for nanotubes 
used as surface coatings in the assembly of multi-structured 
nanodelivery carrier devices to improve intracellular 
cytoplasmic targeting.8 
 
Fig.3. In vitro and in vivo o-MWCNTs effects. (a) Confocal microscopy projection images of HeLa cells exposed to o-MWCNTs for 72 h. Representative image 
demonstrating the apoptotic effect o-MWCNTs. Dying cells (white asterisk) typically display signs indicative of apoptosis. Acentrosomal microtubule 
networks (green channel) and actin microfilament reorganization (red channel) are also patent in most cells. (inset) Apoptotic cells show abnormally long 
cytoplasmic extensions labelled for tubulin (green arrow) and actin (red arrow). (b) Antineoplastic effect of o-MWCNTs in solid melanoma tumours. 
Representative mouse littermates bearing solid melanoma tumours 96 h after a single intra-tumoral injection of resuspension medium (control) or o-
MWCNTs post treatment. Arrows point at the tumour location. (c) Representative solid pigmented melanoma tumoral masses, 96 h after a single injection 
containing 2 µg o-MWCNT treatment. (d) Statistical evaluation of the average tumoral size 96 h post-treatment (single injection containing 2 µg o-MWCNT). 
Biodegradable o-MWCNTs trigger a statistically significant anti-tumoral effect (t= 1.5 n= 146; *= t.90) but indistinguishable to that observed for p-MWCNTs. 
Fig. 4. Raman spectroscopic semi-quantitative analysis of o-MWCNT 
degradation in the tumoral organ. Time indicates days post injection. Pre-
oxidized MWCNTs show a patent peritumoral (t= 1.6 n= 29; *= t.90) and 
intratumoral (t= 1.4; n= 6; *= t.90) biodegradation compared to p-MWCNTs (t= 
0.01; n= 5). 

































































MWCNT oxidation and characterization. 
High-purity MWCNT obtained from Nanocyl NC3100™ were 
dispersed by sonication for 5 minutes in a 3:1 mixture of H2SO4 
(98%)/HNO3 (65%) and were incubated at 37º C under 
continuous shaking.26,45 Resulting as prepared MWCNTs were 
fully characterised by Raman and IR spectroscopy, TGA, mass 
spectrometry and TEM (Fig. S1). Samples were taken at 2 or 9 
h. The acid solution was removed by filtration through a 0.45 
µm and were washed in H2O until pH ~7. o-MWCNTs were 
dispersed and  functionalised with serum-containing culture 
medium as previously described.11 Final working solutions were 
centrifuged 2 min. at 10,000 g to remove micrometric 
aggregates before concentration determination by optical 
absorption at 550 nm. Raman spectra were taken with a Horiba 
T64000 triple spectrometer in the backscattering geometry, a 
647 nm line of a Coherent Innova Spectrum 70c Ar+–Kr+ laser 
and a nitrogen-cooled CCD (Jobin-Yvon Symphony). A confocal 
microscope was used for the intracellular sample Raman 
spectra detection focusing the laser beam into a 1 µm2 with a 
100x objective as described in previous studies.11 MWCNT were 
identified using unique fingerprints characterizing a number of 
well-defined resonances55 such as the dispersive disorder 
induced D band, the tangential G and the D’ band, which are 
attributed using the symmetry analysis to the longitudinal 
optical mode (LO) close to Brillouin zone centre (Γ).62 The D-
band representing the asymmetrical properties of the tubes 
(structural defects), and the G-band the planar carbon atom 
vibrations (linear structure). Raman features such as the radial 
breaching modes (RBM), associated with a small diameter inner 
tube (less than 2 nm), are usually too weak to be observable in 
these large diameter tubes.63,64 As for previous studies, the ratio 
between the areas of the intensity the D and G peaks (AD/AG) 
were used to characterize the structural disorganization that 
MWCNTs undergo during oxidation and intracellular 
degradation.32–34,45 The average intensities of more than 10 
spectra for each time and MWCNT type and experimental time 
are represented in histograms of Fig.  2c. Transmission electron 
microscopy was performed in a JEOL JEM 2100 operated at 120 
kV on ethanol-dispersed samples adsorbed onto a Lacey copper 
grid. Infrared spectra were recorded on a Jasco LE4200 
spectrophotometer. TGA was carried out using a Setaram Setsys 
Evolution 1700 apparatus, ranging from ca 20 - 900º C. Samples 
were placed into platinum crucibles. Measurements were 
performed in nitrogen atmosphere with a heating rate of 10 º 
C/min at a total flow rate of 20 mL/min. A mass spectrometer, 
Pfeiffer OmniStar Prisma, attached to the TG equipment 
allowed us to follow the exhausted CO2 gas. 
 
Cell culture and viability studies. 
HeLa and murine macrophage cells (J774) were grown in 
cultured with Eagle’s Minimum Essential Medium (EMEM, 
Biowhittaker™) and Iscove’s Modified Dulbecco’s Medium 
(IMDM) respectively, containing 10% FBS, and were kept in 
standard conditions. HeLa and J774 cells were exposed to 50 
and 5 µg/mL respectively. Live/dead cell assessment was 
performed automatically using a trypan blue assay (Sigma-
Aldrich) on a Bio-Rad TC-20 cell counter at the indicated times. 
An average of 540,000 macrophage cells were automatically 
counted for each condition.   
 
MWCNT isolation from cells/medium. 
Macrophage cells were exposed to nanotubes in the culture 
medium for 96 h before extraction. Identical amounts of cells 
(ca. 9 x 106 cells of each) and culture medium (500 µL of medium 
originally containing 50 µg/mL of nanotubes) were used for 
nanotube isolation. After cell pelleting, the culture media 
containing the resuspended MWCNTs and the cell pellets were 
processed in parallel for direct comparison. Samples were 
treated successively with 1% Triton X100 phosphate buffered 
saline (PBS), 35% HCl and acetone. 
 
Statistical analysis. 
A two-tailed t-test was used in all other statistical analysis. 
Significance was stablished for a p= 0.05 (*) or a p= 0.01 (**).  
 
Imaging studies. 
Cells were fixed with 4% paraformaldehyde. Actin was stained 
with Phalloidin-Tetramethylrhodamine B isothiocynate and the 
DNA with Hoechst dye (both from Sigma-Aldrich®). 
Microtubules were immunostained with B512 anti- α-tubulin 
antibody (Sigma-Aldrich®) and a secondary goat anti-mouse IgG 
antibody conjugated with Alexa Fluor 488 (Molecular probes®). 
Confocal and phase contrast images were taken using a Nikon 
A1R confocal microscope. Image processing was performed 
with the NIS-Elements Advanced Research software. 
Fluorescent images are pseudo-coloured. 
 
o-MWCNT tumour growth studies in vivo. 
Tumorigenesis was induced by subcutaneous transplantation of 
a total of 2x105 B16-F10 melanoma cells in 10 µL of culture 
medium containing antibiotics following previously described 
procedures.64 Animal experimentation procedures were 
performed according to EU legislation. All animal procedures 
were performed in accordance with the Guidelines for Care and 
Use of Laboratory Animals of The University of Cantabria and 
approved by the Animal Ethics Committee of this University. 
Solid pigmented tumours were single treated 7 days post-
transplant with a unique dose of 2 µg of o-MWCNTs 
resuspended in a volume of 10 µL of culture medium. To reduce 
natural artefacts, littermates were injected in parallel with o-
MWCNTs or the resuspension medium used as excipient. 
Tumours masses were carefully dissected and weighed 4 days 
post injection. Statistical analysis was performed using a t-test. 
The confidence levels and total number of events included in 
the study (n) are indicated in the figures. Quantitative results 
are expressed as mean values with their corresponding 
standard deviation error bars. 
Conclusions 































































In conclusion, here we demonstrate o-MWCNT biodegradation 
in cultured cells and in vivo, at the tumoral site in mice bearing 
malignant tumours produced by transplantation. 
Biodegradation is detectable a few days after these nanotubes 
have had a therapeutic effect. This new property can serve to 
synergistically improve the already existing traditional 
microtubule-stabilizing chemotherapies such as taxol®, but also 
to enhance the in vivo degradation of carbon nanotubes as key 
components in the design of novel nanocarrier devices for their 
use in therapeutic fields other than cancer. 
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Mild oxidation treatments improve in vitro and in 
vivo macrophage biodegradation of carbon 
nanotubes that trigger remarkable anti-tumoral 
effects in malignant melanoma solid tumors 
produced mice. 
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